133 results
Patient factors influencing the selection Of glucose-lowering drugs Other than SGLT2i and metformin in T2D and
and metformin in T2D ... sulfonylurea; T2D ... type 2 diabetes; TZD ... type 2 diabetes; TZD
A1C and eAG
~
*For Educational Purposes Only*

#Diabetes #T2D #DM2 #Table #PrimaryCare #Endocrinology #BloodGlucose #A1C
#Diabetes #T2D
Type 2 Diabetes handout for patients. 
#diabetes #t2d #dm2 #low carb diet #HA1C #patient education #endocrinology
#diabetes #t2d #
The “twin cycles” of diabetes, first introduced by Roy Taylor in 2008.  
#fatty liver #fatty
pancreas #diabetes #t2d
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
patients with T2D
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
patients with T2D
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
patients with T2D
Adverse Effects of Antipsychotic Medications - Comparison Table

First Generation: chlopromazine, haloperidol, fluphenazine 
Second Generation: aripirazole, asenapine,
Side Effects: EPS/TD ... Dyslipidemia, Weight Gain/T2DM
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
lowered CV events in T2DM ... lowered CV events in T2DM ... events in CKD + T2DM ... with or without T2DM ... with or without T2DM
#diabetes #T2DM #antidiabeticagents #oraldiabeticagents

FIGURE 9.1 Glucose-lowering medication in type 2 diabetes: overall approach. For appropriate context,
#diabetes #T2DM ... sulfonylurea; TZD